1. Home
  2. HTFL

as of 11-17-2026 3:45pm EST

$46.80
$0.06
-0.13%
Stocks Nasdaq

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

Founded: 2007 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 2.2B IPO Year: 2025
Target Price: $65.00 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.63 EPS Growth: 82.37
52 Week Low/High: $20.13 - $60.66 Next Earning Date: 11-12-2026
Revenue: $176,034,000 Revenue Growth: 39.92%
Revenue Growth (this year): 49.74% Revenue Growth (next year): 24.54%
P/E Ratio: -74.38 Index:
Free Cash Flow: -59048000.0 FCF Growth: N/A

AI-Powered HTFL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

sell
Model Precision: 75.76%
75.76%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Heartflow Inc. (HTFL)

Farquhar John C.M.

Chief Executive Officer

Sell
HTFL Nov 10, 2026

Avg Cost/Share

$55.74

Shares

38,900

Total Value

$2,168,286.00

Owned After

251,983

SEC Form 4

Verghese Vikram

Chief Financial Officer

Sell
HTFL Nov 9, 2026

Avg Cost/Share

$53.15

Shares

3,587

Total Value

$190,649.05

Owned After

149,587

SEC Form 4

Rogers Campbell

Chief Medical Officer

Sell
HTFL Oct 22, 2026

Avg Cost/Share

$55.01

Shares

23,933

Total Value

$1,316,554.33

Owned After

73,453

SEC Form 4

Farquhar John C.M.

Chief Executive Officer

Sell
HTFL Oct 12, 2026

Avg Cost/Share

$49.57

Shares

38,900

Total Value

$1,928,195.20

Owned After

251,983

SEC Form 4

Verghese Vikram

Chief Financial Officer

Sell
HTFL Sep 8, 2026

Avg Cost/Share

$50.03

Shares

6,640

Total Value

$332,211.82

Owned After

149,587

SEC Form 4

Verghese Vikram

Chief Financial Officer

Sell
HTFL Sep 3, 2026

Avg Cost/Share

$49.69

Shares

27,540

Total Value

$1,368,470.86

Owned After

149,587

SEC Form 4

Verghese Vikram

Chief Financial Officer

Sell
HTFL Sep 2, 2026

Avg Cost/Share

$50.60

Shares

5,876

Total Value

$297,325.60

Owned After

149,587

SEC Form 4

Farquhar John C.M.

Chief Executive Officer

Sell
HTFL Aug 21, 2026

Avg Cost/Share

$50.00

Shares

27,230

Total Value

$1,361,500.00

Owned After

251,983

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 12, 2026 · 100% conf.

AI Prediction BUY

1D

+14.47%

$68.36

Act: -18.78%

5D

+21.90%

$72.80

20D

+28.83%

$76.94

Price: $59.72 Prob +5D: 100% AUC: 1.000
0001464521-26-000171

EX-99.1

2 htfl-20261112xex99_1.htm

EX-99.1

Exhibit 991 20261112

Exhibit 99.1

Heartflow Reports Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO — November 12, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Highlights

Ï

Total revenue of $72.9 million, a 57% increase year-over-year

Ï

Gross margin of 83.6%, non-GAAP gross margin of 83.8%

Ï

Net operating loss of $13.8 million; non-GAAP net operating loss of $5.0 million

2026 Annual Guidance

Ï

Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year)

Ï

Non-GAAP gross margin of approximately 82.5%, compared to previous guidance of approximately 82%

“Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters,” said John Farquhar, President and CEO of Heartflow. “Our core FFRCT business remains durable, our installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan, with utilization broadening across a wider share of applicable CCTAs. The CCTA market continues to grow rapidly and remains significantly underpenetrated. Strong performance across our diagnostic platform, along with disciplined execution of our commercial, innovation and clinical initiatives, gives us the confidence to raise our 2026 guidance once again. With continued momentum and a scaling business, we believe we are well-positioned to extend our market leadership, and we have increased confidence in our path to profitability.”

Third Quarter 2026 Financial Results

Total revenue was $72.9 million, a 57% increase year-over-year. U.S. revenue was $67.9 million, a 60% increase year-over-year. International and other revenue was $4.9 million, a 29% increase year-over-year. The year-over-year increase in total global revenue was primarily attributable to an increase in total U.S. FFRCT revenue case volume and an increase in total U.S. Plaque revenue case volume.

Gross profit was $60.9 million, compared to $35.4 million in the prior year period. Non-GAAP gross profit was $61.1 million, compared to $35.5 million in the prior year period.

Gross margin was 83.6%, compared to 76.5% in the prior year period. Non-GAAP gross margin was 83.8%, compared to 76.8% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in total revenue case volume, an increase in total U.S. Plaque revenue case volume, and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel.

Total operating expenses were $74.8 million, or 103% of total revenue, compared to $50.5 million, or 109% of total revenue, in the prior year period. Non-GAAP total operating expenses were $66.1 million, or 91% of total revenue, compared to $46.7 million, or 101% of total revenue, in the prior year period. The year-over-year operating expense increase was primarily attributable to increased investment in sales personnel and related expenses, as well as increased investments in technology and clinical research.

Net operating loss was $13.8 million, compared to $15.1 million in the prior year period. Non-GAAP net operating loss was $5.0 million, compared to $11.1 million in the prior year period.

Net loss was $11.5 million, or ($0.13) net loss per share, compared to $50.9 million, or ($1.04) net loss per share, in the prior year period. Net loss in the prior year period included a $32.1 million noncash charge from the remeasurement of the fair value of the Company’s warrant liability, a $4.8 million noncash benefit from the remeasurement of the fair value of the Company’s derivative liability, and a $6.4 million loss on extinguishment of debt from the full prepayment of the Company’s term loan in August 2025.

Non-GAAP net loss was $2.7 million, or ($0.03) non-GAAP net loss per share, compared to $13.2 million, or ($0.27) non-GAAP net loss per share, in the prior year period.

Adjusted EBITDA was ($3.6) million, compared to ($9.8) million in the prior year period.

Cash, cash equivalents and investments totaled $253.0 million as of September 30, 2026.

For additional information regarding non-GAAP financial measures, see “Use of Non-GAAP Measures,” “Heartflow GAAP to Non-GAAP Reconciliations” and “Reconciliation of GAAP Net Loss to Adjusted EBITDA” below.

Webcast and Conference Call Details

Heartflow will host a conference call today, November  12, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2026 financial results. Those interested in listening

2026
Q2

Q2 2026 Earnings

8-K

Aug 13, 2026

0001464521-26-000129

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K

May 14, 2026

0001464521-26-000069

EX-99.1

2 htfl-20260514xex99_1.htm

EX-99.1

Exhibit 99.1 2026.05.14

Exhibit 99.1

Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO — May 14, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Highlights

·

Total revenue of $52.6 million, a 41% increase year-over-year

·

Gross margin of 80.2%, non-GAAP gross margin of 80.5%

·

Net operating loss of $29.5 million, including a $7.5 million non-cash impairment charge associated with facilities optimization and headquarters relocation to San Francisco. Non-GAAP net operating loss was $15.5 million

2026 Annual Guidance

·

Total revenue of $228 million to $232 million (approximately 29% to 32% growth year-over-year), compared to previous guidance of $218 million to $222 million (approximately 24% to 26% growth year-over-year)

·

Non-GAAP gross margin of approximately 81%, compared to previous guidance of 80% to 81%

“Heartflow entered 2026 with unprecedented momentum, expanding the category leadership we established over the last several years,” said John Farquhar, President and CEO of Heartflow. “Our AI-driven platform, deeply embedded commercial footprint, and the world’s largest database that recently expanded to over 200 million annotated CCTA images combine to create a foundational advantage that grows stronger with every quarter. The growth of our core FFRCT business remains durable, and adoption of Heartflow Plaque Analysis is ramping ahead of schedule. Most importantly, by helping physicians guide the care of over 650,000 patients worldwide, Heartflow has achieved an unrivaled scale of real-world experience. As the architects of this category, we continue to extend our leadership position, becoming the AI operating system of record for the detection, diagnosis, management, and treatment planning of coronary artery disease.”

First Quarter 2026 Financial Results

Total revenue was $52.6 million, a 41% increase year-over-year. U.S. revenue was $48.3 million, a 42% increase year-over-year. International and other revenue was $4.3 million, a 34% increase year-over-year. The year-over-year increase in total global revenue was primarily attributable to an increase in total U.S. FFRCT volume.

Gross profit was $42.2 million, compared to $27.9 million in the prior year period. Non-GAAP gross profit was $42.3 million, compared to $28.0 million in the prior year period.

Gross margin was 80.2%, compared to 75.1% in the prior year period. Non-GAAP gross margin was 80.5%, compared to 75.3% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in revenue case volume and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel.

Total operating expenses were $71.7 million, or 136% of total revenue, compared to $45.4 million, or 122% of total revenue, in the prior year period. GAAP operating expenses also included a $7.5 million non-cash impairment charge related to the right-of-use asset for our Mountain View, California facility. The Company optimized its facilities footprint and relocated its headquarters to San Francisco. Non-GAAP total operating expenses were $57.8 million, or 110% of total revenue, compared to $43.0 million, or 116% of total revenue, in the prior year period. The year-over-year operating expense increase was primarily attributable to increased investment in sales personnel and related expenses, as well as increased investments in technology and clinical research.

Net operating loss was $29.5 million, compared to $17.5 million in the prior year period. Non-GAAP net operating loss was $15.5 million, compared to $15.0 million in the prior year period.

Net loss was $27.4 million, or ($0.32) net loss per share, compared to $32.3 million, or ($5.25) net loss per share, in the prior year period. Non-GAAP net loss was $13.3 million, or ($0.16) non-GAAP net loss per share, compared to $19.2 million, or ($3.11) non-GAAP net loss per share, in the prior year period.

Adjusted EBITDA was ($14.0) million, compared to ($13.6) million in the prior year period.

Cash, cash equivalents and investments totaled $254.9 million as of March 31, 2026.

For additional information regarding non-GAAP financial measures, see “Use of Non-GAAP Measures,” “Heartflow GAAP to Non-GAAP Reconciliations” and “Reconciliation of GAAP Net Loss to Adjusted EBITDA” below.

Webcast and Conference Call Details

Heartflow will host a conference call today, May  14, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its first quarter 2026 financial results. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a uniqu

Share on Social Networks: